Brief: Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In Oral Treatment Of Moderate To Severe Psoriasis
11/07/2022 12:33
July 11 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE TO SUBMIT FDA & EMA REGISTRATION PLANS FOR
PICLIDENOSON
IN THE ORAL TREATMENT OF MODERATE TO SEVERE PSORIASIS
Source text for Eikon: ID:nBw8zZY7za
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage